Ignite Creation Date:
2025-12-24 @ 9:23 PM
Ignite Modification Date:
2025-12-28 @ 4:23 AM
Study NCT ID:
NCT04570332
Status:
COMPLETED
Last Update Posted:
2025-11-26
First Post:
2020-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Sponsor:
Highlight Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-30
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-11-04
Completion Date Type:
ACTUAL
First Submit Date:
2020-09-22
First Submit QC Date:
None
Study First Post Date:
2020-09-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-12-06
Results First Submit QC Date:
None
Results First Post Date:
2025-11-26
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-14
Last Update Post Date:
2025-11-26
Last Update Post Date Type:
ESTIMATED